PR Newswire BiotechOriginal article
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
Conference(Z)-EndoxifenPositive
AI Analysis
Summary
Atossa Therapeutics presented preclinical data on (Z)-Endoxifen demonstrating dual estrogen receptor and PKC-β/AKT pathway modulation as a potential therapeutic strategy for McCune-Albright Syndrome at the AACR Special Conference on Rare Cancers.
Outcome Details
Preclinical data poster presentation highlighting dual estrogen receptor and PKC-β/AKT pathway modulation
Importance:3/10
Sentiment:
0.40
preclinical dataconference presentationrare diseasemechanism of actionMcCune-Albright Syndrome
Related Companies
Read the original article
Published by PR Newswire Biotech on July 21, 2026 12:30 PM